Alligator Bioscience Ab

Peter Bo Joakim Ellmark

Eva Maria Dahlen

Carl Arne Krister Borrebaeck

Malin Marie Lindstedt

Sissela Rachel Linn Broos

Eva Maria DAHLÉN

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1&#xd7;10M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells

Anti-CD40 antibodies and methods of treating cancer

The present invention provides pharmaceutical compositions comprising an immunostimulatory polypeptide and polyglutamic acid (PGA) nanoparticles, formulated in a pharmaceutically acceptable diluent, carrier or excipient. Such compositions have utility in stimulating the immune system in subjects, with the components capable of interacting synergistically. The invention further provides uses of the compositions of the invention, for example in the treatment of cancer, and kit and components for use in the same.

Compositions comprising polyglutamic acid nanoparticles and CD40 agonists

Growing community of inventors

Lund, Sweden

Peter Bo Joakim Ellmark